Understanding the complexity of the tumour immune microenvironment in tissues from preclinical mouse models through to patients on clinical trial provides valuable information for the drug discovery process.
At HistologiX we offer validated and optimised IHC immuno-oncology biomarker assays, together with next generation quantitative image analysis tools to deliver valuable immunological insight into tumour immune processes.
Our robust approach to the identification, quantification, localisation, and spatial relationships of immuno-oncology biomarkers in tumour tissues, and the ability to interpret data from these assays, supports clients in making informed decisions for advancing their immunotherapeutic strategy to market.
Spatial distribution of immune cells within the tumour microenvironment is likely to be as important as the quantitative assessment of immune cell densities.
By defining the interface between tumour and stroma, the profile of immune cell subsets within distinct bands either side of the invasive margin can be quantified.
Significant insights can be made into the impact of immunotherapies on tumour immune processes and classification of different tumour types by direct interrogation of the tumour-immune interface.
Histologix provides the Pharmaceutical and Biotechnology industry with specialist pathology services to assist drug development programmes ranging from Discovery, regulatory preclinical safety testing through to clinical trials and include human tissue sourcing, histology, medical and veterinary histopathology, immunohistochemistry, digital pathology and image analysis. These are technologies that have been developed with to meet current and future requirements of targeted therapy.
Through inward investment the services provided by Histologix Ltd use a range of highly sophisticated technologies and platforms aimed at standardising the various processes involved in order to achieve data generation that is consistent, accurate and reproducible and will assist our clients in the development of their drug programmes.
Histologix is a privately owned contract research organisation that provides specialist pathology services for the Pharmaceutical and Biotechnology industry. Set up in 2005 by industry specialists, Histologix is a GLP/GCP accredited, HTA-licenced company with an extensive and impressive track record of successfully delivering a range of IHC/ISH assays to large and small Pharma/Biotechnology companies and is a preferred supplier of these services to a number of companies.
Find out which conference Histologix is exhibiting at, updated news issues and current vacancies.